WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018024237) ANTI-PD-L1 NANOBODY AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/024237    International Application No.:    PCT/CN2017/095884
Publication Date: 08.02.2018 International Filing Date: 03.08.2017
IPC:
C07K 16/28 (2006.01), C12N 15/13 (2006.01), C12N 15/85 (2006.01), A61K 39/395 (2006.01), A61K 51/10 (2006.01), A61P 35/00 (2006.01)
Applicants: INNOVENT BIOLOGICS (SUZHOU) CO., LTD [CN/CN]; 168 Dongping Street, Suzhou Industrial Park Suzhou, Jiangsu 215123 (CN)
Inventors: SHEN, Xiaoning; (CN).
MIAO, Xiaoniu; (CN).
LIU, Xiaolin; (CN)
Agent: XU & PARTNERS,LLC.; Room No.106, Building No.1 Universal High-Tech Plaza 958 Zhen Bei Road, Putuo District Shanghai 200333 (CN)
Priority Data:
201610634596.X 04.08.2016 CN
Title (EN) ANTI-PD-L1 NANOBODY AND USE THEREOF
(FR) NANOCORPS ANTI-PD-L1 ET SON UTILISATION
(ZH) 抗PD-L1纳米抗体及其应用
Abstract: front page image
(EN)Disclosed is a nanobody against the human programmed death factor PD-L1. The antibody has the function of blocking the binding of PD-L1 to the receptor PD-1. Disclosed are the nanobody and the gene sequence encoding the nanobody, the corresponding expression vector and the host cell capable of expressing the nanobody, and the method for producing the nanobody. At the same time, also disclosed is the sequence of the humanized PD-L1 nanobody. The humanized nanobody still has the function of blocking the binding of PD-L1 to PD-1, and has a relatively high affinity and a relatively good specificity.
(FR)L'invention concerne un nanocorps contre le facteur de mort humain programmé PD-L1. L'anticorps a pour fonction de bloquer la liaison de PD-L1 au récepteur PD-1. L'invention concerne le nanocorps et la séquence de gènes codant pour le nanocorps, le vecteur d'expression correspondant et la cellule hôte capables d'exprimer le nanocorps, et le procédé de production du nanocorps. En même temps, l'invention concerne également la séquence du nanocorps humain PD-L1. Le nanocorps humanisé a encore la fonction de bloquer la liaison de PD-L1 à PD-1, et a une affinité relativement élevée et une spécificité relativement bonne.
(ZH)一种针对人程序性死亡因子PD-L1的纳米抗体,该抗体具有阻断PD-L1与受体PD-1结合的功能。公开了该纳米抗体及编码该纳米抗体的基因序列,相应的表达载体和能够表达该纳米抗体的宿主细胞,以及该纳米抗体的生产方法。同时还公开了人源化的PD-L1纳米抗体序列,人源化后的纳米抗体仍然具有阻断PD-L1与PD-1结合的功能、较高的亲和力及较好的特异性。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)